Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-30. Numbers and descriptions here follow the published literature rather than marketing material.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
In materials science and molecular biology, thermostability is the ability of a substance to resist irreversible change in its chemical or physical structure, often by resisting decomposition or polymerization, at a high relative temperature. Thermostable materials may be used industrially as fire retardants. A thermostable plastic, an uncommon and unconventional term, is likely to refer to a thermosetting plastic that cannot be reshaped when heated, than to a thermoplastic that can be remelted and recast. Thermostability is also a property of some proteins. To be a thermostable protein means to be resistant to changes in protein structure due to applied heat.
After ingesting psilocybin, the user may experience a wide range of emotional effects, which can include disorientation, lethargy, giddiness, euphoria, joy, and depression. In one study, 31% of volunteers given a high dose reported feelings of significant fear and 17% experienced transient paranoia. In studies at Johns Hopkins University, among those given a moderate dose (but enough to "give a high probability of a profound and beneficial experience"), negative experiences were rare, whereas one-third of those given a high dose experienced anxiety or paranoia. Low doses can induce hallucinatory effects. Closed-eye hallucinations may occur, where the affected person sees multicolored geometric shapes and vivid imaginative sequences. Some people report synesthesia, such as tactile sensations when viewing colors. At higher doses, psilocybin can lead to "intensification of affective responses, enhanced ability for introspection, regression to primitive and childlike thinking, and activation of vivid memory traces with pronounced emotional undertones". Open-eye visual hallucinations are common and may be very detailed, although rarely confused with reality. Psilocybin is known to strongly affect the subjective experience of the passage of time. Users often feel as if time is slowed down, resulting in the perception that "minutes appear to be hours" or "time is standing still".
Douglas Farah, a national security consultant and president of IBI Consultants, compared the US invasion of Panama to the current geopolitical situation in Venezuela, warning that although the Panama operation was a relatively swift military victory, occupying Venezuela would present significantly greater challenges. Professor Sultan Barakat, an expert from Qatar's Hamad Bin Khalifa University, argued that the US actions in Venezuela have set a dangerous precedent that could influence China's approach to Taiwan. He also warned that this precedent could potentially encourage Russian president Vladimir Putin to adopt a more aggressive stance toward Ukrainian president Volodymyr Zelenskyy. The Washington Post wrote that the lack of transparency and separation between business and diplomacy in the Trump administration's dictation of policy to the Venezuelan government has "raised questions about oversight in the affairs of the resource-rich nation that is emerging as a U.S. neo-colony."
==== Drug-delivery and biological compatibility ==== Nanodiamonds can self-assemble and a wide range of small molecules, proteins antibodies, therapeutics, and nucleic acids can bind to its surface allowing for drug delivery, protein-mimicking, and surgical implants. Other potential biomedical applications are the use of nanodiamonds as support for solid-phase peptide synthesis and as sorbents for detoxification and separation and fluorescent nanodiamonds for biomedical imaging. Nanodiamonds are capable of biocompatibility, the ability to carry a broad range of therapeutics, dispersibility in water and scalability, and the potential for targeted therapy all properties needed for a drug delivery platform. The small size, stable core, rich surface chemistry, ability to self-assemble, and low cytotoxicity of nanodiamonds have led to suggestions that they could be used to mimic globular proteins. Nanodiamonds have been mostly studied as potential injectable therapeutic agents for generalized drug delivery, but it has also been shown that films of Parylene nanodiamond composites can be used for localized sustained release of drugs over periods ranging from two days to one month.
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 is an enzyme that in humans is encoded by the PLOD3 gene. The protein encoded by this gene is a membrane-bound homodimeric enzyme that is localized to the cisternae of the rough endoplasmic reticulum. The enzyme (cofactors iron and ascorbate) catalyzes the hydroxylation of lysyl residues in collagen-like peptides. The resultant hydroxylysyl groups are attachment sites for carbohydrates in collagen and thus are critical for the stability of intermolecular crosslinks. Some patients with Ehlers-Danlos syndrome type VIB have deficiencies in lysyl hydroxylase activity.
Sources: en.wikipedia.org
==== Premier League debut ==== Townsend remained with Tottenham for the first half of their 2012–13 season, with the club now under a new manager, André Villas-Boas, who replaced Redknapp in the summer. He made his Premier League debut with a late substitution appearance on 16 September. Although appearing a further four times in the Premier League, these were all still late substitute appearances. Outside the league he made a further five appearances, once in the League Cup and FA Cup respectively, and three times in the Europa League. He scored his third Tottenham goal with a "superb low left-foot shot into the bottom corner from just outside the area" in a 3–0 victory against Carlisle United in the League Cup third round.
Berkelium is a synthetic chemical element; it has symbol Bk and atomic number 97. It is a member of the actinide and transuranium element series. It is named after the city of Berkeley, California, the location of the Lawrence Berkeley National Laboratory (then the University of California Radiation Laboratory) where it was discovered in December 1949. Berkelium was the fifth transuranium element discovered after neptunium, plutonium, curium and americium. The major isotope of berkelium, 249Bk, is synthesized in minute quantities in dedicated high-flux nuclear reactors, mainly at the Oak Ridge National Laboratory in Tennessee, United States, and at the Research Institute of Atomic Reactors in Dimitrovgrad, Russia. The longest-lived and second-most important isotope, 247Bk, can be synthesized via irradiation of 244Cm with high-energy alpha particles. Just over one gram of berkelium has been produced in the United States since 1967. There is no practical application of berkelium outside scientific research which is mostly directed at the synthesis of heavier transuranium elements and superheavy elements. A 22-milligram batch of berkelium-249 was prepared during a 250-day irradiation period and then purified for a further 90 days at Oak Ridge in 2009. This sample was used to synthesize the new element tennessine for the first time in 2009 at the Joint Institute for Nuclear Research, Russia, after it was bombarded with calcium-48 ions for 150 days. This was the culmination of the Russia–US collaboration on the synthesis of the heaviest elements on the periodic table.
γ-Butyrolactone (GBL) or gamma-butyrolactone is an organic compound with the formula O=CO(CH2)3. It is a hygroscopic, colorless, water-miscible liquid with a pleasant odor. It is the simplest 4-carbon lactone. It is mainly used as an intermediate in the production of other chemicals, such as N-methyl-2-pyrrolidone. In humans, GBL acts as a prodrug for gamma-hydroxybutyric acid (GHB) and is often used as a recreational drug. GHB acts as a central nervous system (CNS) depressant with effects similar to those of barbiturates.
== Applications == CagriSema is under investigation to treat type 2 diabetes and obesity. Preliminary trial results found a greater weight loss compared to either semaglutide or cagrilintide alone. HbA1c was significantly improved compared to cagrilintide alone and non-significantly better than semaglutide alone. In a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, comparable in efficacy to tirzepatide.
Sources: en.wikipedia.org
Albersheim P, Killias U (1962). "Studies relating to the purification and properties of pectin transeliminase". Arch. Biochem. Biophys. 97 (1): 107–15. doi:10.1016/0003-9861(62)90050-4. PMID 13860094. Edstrom RD, Phaff HJ (1964). "Purification and Certain Properties of Pectin trans-Eliminase from Aspergillus fonsecaeus". J. Biol. Chem. 239 (8): 2403–8. doi:10.1016/S0021-9258(18)93866-4. PMID 14235514. Edstrom RD, Phaff HJ (1964). "Eliminative Cleavage of Pectin and of Oligogalacturonide Methyl Esters by Pectin trans-Eliminase". J. Biol. Chem. 239 (8): 2409–15. doi:10.1016/S0021-9258(18)93867-6. PMID 14235515. Nagel CW, Vaughn RH (1961). "The degradation of oligogalacturonides by the polygalacturonase of Bacillus polymyxa". Arch. Biochem. Biophys. 94 (2): 328–32. doi:10.1016/0003-9861(61)90047-9. PMID 13727438. Nasuno S, Starr MP (1967). "Polygalacturonic acid trans-eliminase of Xanthomonas campestris". Biochem. J. 104 (1): 178–85. doi:10.1042/bj1040178. PMC 1270559. PMID 6035509. Pickersgill R, Jenkins J (1997). "Two crystal structures of pectin lyase A from Aspergillus reveal a pH-driven conformational change and striking divergence in the substrate-binding clefts of pectin and pectate lyases". Structure. 5 (5): 677–89. doi:10.1016/S0969-2126(97)00222-0. PMID 9195887.
In 2019, biologists with the Iowa Department of Natural Resources confirmed documentation of an American black bear living year-round in woodlands near the town of Decorah in northeastern Iowa, believed to be the first instance of a resident black bear in Iowa since the 1880s. Surveys taken from 35 states in the early 1990s indicated that American black bear populations were either stable or increasing, except in Idaho and New Mexico. The population in the United States was estimated to range between 339,000 and 465,000 in 2011, though this estimate does not include data from Alaska, Idaho, South Dakota, Texas or Wyoming, whose populations were not recorded in the survey. California has the largest population of the species in any of the 48 contiguous United States. The estimated 25,000-35,000 black bears in 2017 grew to 60,000 by 2026. In 2020 there were about 1,500 bears in Great Smoky Mountains National Park, where the population density is about two per square mile. In western North Carolina, the black bear population has increased from about 3,000 in the early 2000s to over 8,000 in the 2020s. As of 1993, known black bear populations in Mexico existed in four areas, though knowledge on the distribution of populations outside those areas has not been updated since 1959. Mexico is the only country where the species is classified as "endangered".
=== Cytoprotective effects === When APC is bound to EPCR, it performs a number of important cytoprotective (i.e. cell-protecting) functions, most of which are known to require EPCR and PAR-1. These include regulating gene expression, anti-inflammatory effects, antiapoptotic effects and protecting endothelial barrier function. Treatment of cells with APC demonstrates that its gene expression modulation effectively controls major pathways for inflammatory and apoptotic behaviour. There are about 20 genes that are up-regulated by protein C, and 20 genes that are down-regulated: the former are generally anti-inflammatory and antiapoptotic pathways, while the latter tend to be proinflammatory and proapoptotic. APC's mechanisms for altering gene expression profiles are not well understood, but it is believed that they at least partly involve an inhibitory effect on transcription factor activity. Important proteins that APC up-regulates include Bcl-2, eNOS and IAP. APC effects significant down-regulation of p53 and Bax. APC has anti-inflammatory effects on endothelial cells and leukocytes. APC affects endothelial cells by inhibiting inflammatory mediator release and down-regulating vascular adhesion molecules. This reduces leukocyte adhesion and infiltration into tissues, while also limiting damage to underlying tissue. APC supports endothelial barrier function and reduces chemotaxis.
Glycomics is the comprehensive study of glycomes (the entire complement of sugars, whether free or present in more complex molecules of an organism), including genetic, physiologic, pathologic, and other aspects. Glycomics "is the systematic study of all glycan structures of a given cell type or organism" and is a subset of glycobiology. The term glycomics is derived from the chemical prefix for sweetness or a sugar, "glyco-", and was formed to follow the omics naming convention established by genomics (which deals with genes) and proteomics (which deals with proteins).
== Heterotrophic versus autotrophic origin == The heterotrophic hypothesis, also known as the Oparin–Haldane hypothesis, proposes that the first organisms were heterotrophs that obtained energy and carbon from organic molecules accumulated through abiotic synthesis in the primitive environment. Alexander Oparin (1924) and J.B.S. Haldane (1929) independently argued that since heterotrophic anaerobes are metabolically simpler than autotrophs, heterotrophy must have evolved first. This concept traces back to Charles Darwin's 1871 speculation about life originating in "some warm little pond" containing ammonia, phosphoric salts, and energy sources where protein compounds could form. The Miller–Urey experiment (1953) provided experimental support by demonstrating abiotic synthesis of amino acids and other biochemically significant molecules under simulated early Earth conditions. The autotrophic hypothesis proposes that the earliest life forms were autotrophs capable of synthesizing organic molecules from inorganic carbon (CO2) using geochemical energy. Günter Wächtershäuser's iron–sulfur world theory suggests that life originated at hydrothermal vents where iron sulfide and nickel sulfide minerals catalyzed carbon fixation from volcanic gases. Experimental work demonstrated synthesis of activated acetic acid and peptide bond formation on (Fe,Ni)S surfaces under prebiotic conditions. The two hypotheses are not mutually exclusive; the FeS/H2S reducing chemistry central to autotrophic models is also consistent with heterotrophic scenarios.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.